Abstract:
A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products.
Abstract:
A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.
Abstract:
It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
Abstract:
The present invention concerns a method for separating different oligosaccharides having at least one carboxylic acid group by contacting them with basic anion exchange resins.
Abstract:
Disclosed herein are systems and methods for the purification of human milk oligosaccharides (HMOs). The HMOs can be purified from a suspension containing one or more of a bacterial biomass, cell fragments, small particles, and biomolecules. Advantageously, the solution can be pre-treated prior to centrifuging to form a clarified supernatant containing purified HMOs.
Abstract:
The present invention relates to a genetically modified cell expressing an α-1,2-fucosyltransferase and an α-1,3-fucosyltransferase, and a transporter protein of the major facilitator superfamily (MFS) and to a method for recombinant production of human milk oligosaccharides (HMOs) using said genetically modified cell. More particularly, the invention provides a method for recombinant production of and a genetically modified cell capable of producing difucosyllactose (DFL) as the most abundant HMO, with a relatively low content of 3-fucosyllactose (3FL) and/or 2′-fucosyllactose (2′FL).
Abstract:
The present invention relates to the isolation and purification of sialylated oligosaccharides from an aqueous medium in which they are produced.
Abstract:
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.
Abstract:
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.